| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 01/02/2002 | EP1165528A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/02/2002 | EP1165519A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| 01/02/2002 | EP1165518A2 Benzimidazole and imidazolopyridine derivatives, their preparation and their use as selective modulators of bradykinin b2 (= bk-2) receptors |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165514A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165491A1 Lta4 hydrolase inhibitors |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165104A1 Lactic acid bacteria strains capable of preventing diarrhoea |
| 01/02/2002 | EP1165087A1 In vivo stain compounds and methods of use to identify dysplastic tissue |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165082A1 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1165080A2 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165060A1 Treatment of gallstones |
| 01/02/2002 | EP1165057A2 Endodontic fibers and methods of use therefor |
| 01/02/2002 | EP1165013A2 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1164874A1 Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions |
| 01/02/2002 | EP1001801B1 Product comprising at least a double stranded rna combined with at least an interferon for the treatment of viral hepatitis |
| 01/02/2002 | EP0472588B2 Use of alpha-d-galactosidase for the preparation of a pharmaceutical composition for reducing gastro-intestinal distress due to alpha-d-galactoside-linked sugars. |
| 01/02/2002 | CN1329620A Analogues of GLP-1 |
| 01/02/2002 | CN1329613A New compounds |
| 01/02/2002 | CN1329609A Tetrahydrobenza epine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
| 01/02/2002 | CN1329601A New benzimidazolone-benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 01/02/2002 | CN1329599A 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 01/02/2002 | CN1329597A Pyridinium derivatives for treatment of diabetic and aging-related vascular complications |
| 01/02/2002 | CN1329594A Ureidopiperidine derivatives as selective human NK3 receptor antagonists |
| 01/02/2002 | CN1329590A Therapeutic product and its use |
| 01/02/2002 | CN1329589A N-aralkylaminotetralins as ligands for neuroptide YY5 receptor |
| 01/02/2002 | CN1329506A Formulation with an improved therapeutic range, cntainng nucleotide synthesis inhibitors |
| 01/02/2002 | CN1329497A Cmbination therapy to treat hepatitis b virus |
| 01/02/2002 | CN1329169A Production of oral vaccine and antibiotic peptide active matter by using transgenic saline algae |
| 01/02/2002 | CN1329003A Preparation method of optical purity lansoprazole |
| 01/02/2002 | CN1328838A Liquid medicine for preventing and curing dental caries and edontopathy and its preparation process |
| 01/02/2002 | CN1328834A Capsule for curing cholecystitis |
| 01/02/2002 | CN1076971C Powder for removing infantile malnutrition |
| 01/01/2002 | WO2002089812A1 Composition for treating drug-induced constipation with 15-keto-prostaglandins |
| 01/01/2002 | US6335459 Prostaglandin i2 receptor modulators; treating tissue necrosis, premature uterine contraction, gastric ulceration, sexual dysfunction, menstrual pain and improper wound healing, immunoregulation, platelet aggregation or neutrophil function |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335352 Administering heterocyclic cyanoguanidine derivatives as chemokine inhibitors |
| 01/01/2002 | US6335351 Antiulcer agents and antisecretory agents of gastric juice; gastrointestinal disorder and psoriasis treatment; adenosine triphosphatase inhibitors |
| 01/01/2002 | US6335349 Agents that reduce levels of tumor necrosis factor; anticarcinogenic and antiinflammatory agents; treatment of autoimmune diseases |
| 01/01/2002 | US6335343 Inhibitors of prenyl-protein transferase |
| 01/01/2002 | US6335338 Calcilytic compounds |
| 01/01/2002 | US6335334 Hypertensive agents, anticoagulants; cardiovascular and sexual disorders, angina pectoris, and atherosclerosis |
| 01/01/2002 | US6335333 Matrix metalloproteinase inhibitors |
| 01/01/2002 | US6335332 Barbituric acid derivatives with antimetastatic and antitumor activity |
| 01/01/2002 | US6335329 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 01/01/2002 | US6335327 1-benzazepine derivatives; agonists or antagonists of vasopressin and/or oxytocin |
| 01/01/2002 | US6335028 Implantable particles for urinary incontinence |
| 01/01/2002 | US6335023 Vehicles and oligosaccharide aldonic acids |
| 12/29/2001 | CA2351904A1 Target |
| 12/29/2001 | CA2351902A1 Use of growth hormone secretagogues for stimulating or increasing appetite |
| 12/27/2001 | WO2001098497A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| 12/27/2001 | WO2001098494A1 Ligand to gpr8 and dna thereof |
| 12/27/2001 | WO2001098493A1 Insulin-like growth factor-binding protein |
| 12/27/2001 | WO2001098490A1 A g-protein coupled receptor |
| 12/27/2001 | WO2001098473A2 Method for isolating and purifying a protein and resulting protein |
| 12/27/2001 | WO2001098468A2 Proteases |
| 12/27/2001 | WO2001098364A2 Peptides, compositions and methods for the treatment of burkholderia cepacia |
| 12/27/2001 | WO2001098362A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/27/2001 | WO2001098360A2 Gp354 nucleic acids and polypeptides |
| 12/27/2001 | WO2001098354A2 Human receptors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098351A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098347A1 Canine liver cell growth factor |
| 12/27/2001 | WO2001098344A2 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | WO2001098333A2 Modification of hepatitis b core antigen |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098331A2 Glucagon-like peptide-1 analogs |
| 12/27/2001 | WO2001098330A2 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 12/27/2001 | WO2001098324A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098306A1 Compounds for treating impaired fundic relaxation |
| 12/27/2001 | WO2001098301A1 Pyrazolopyridine compounds and use thereof as drugs |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | WO2001098289A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | WO2001098279A2 Bis-arylsulfones |
| 12/27/2001 | WO2001098278A1 Methods and compositions utilizing quinazolinones |
| 12/27/2001 | WO2001098273A1 Novel compounds |
| 12/27/2001 | WO2001098270A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098269A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098268A2 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098267A1 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity |
| 12/27/2001 | WO2001098253A2 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists |
| 12/27/2001 | WO2001098251A1 Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098250A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001097864A1 The process of extracting from haw-pit by dry distillation and its device |
| 12/27/2001 | WO2001097856A2 An orphan nuclear receptor |
| 12/27/2001 | WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097834A1 Matrix protein compositions for dentin regeneration |
| 12/27/2001 | WO2001097821A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor. |
| 12/27/2001 | WO2001097810A2 Use of therapeutic benzamide derivatives |
| 12/27/2001 | WO2001097806A1 Cox-2 inhibitors and the prevention of the side effects of radiation therapy |
| 12/27/2001 | WO2001097803A1 Pharmaceutical preparations comprising racecadotril (acetorphan) |